Pediatrik Nöroloji Hastalarında Aşılama
Özet
Çocuk nörolojik hastalıkları olan bireyler, enfeksiyonlara yatkınlıkları nedeniyle aşıyla önlenebilir hastalıklara karşı yüksek risk altındadır. Enfeksiyonların bu hastalarda nörolojik prognozu olumsuz etkileyebilmesi nedeniyle, aşıların zamanında uygulanması yaşam kalitesini artırmak için en etkili yoldur. Aşı sonrası febril konvülsiyon veya nörolojik komplikasyon korkusu, rutin aşılamaların aksatılması için bir gerekçe oluşturmamalıdır. İmmünsüpresif tedavi alanlar dışında, nörolojik hastalar genel aşı takvimine uygun şekilde aşılanmalı ve özel durumlar uzman görüşüyle değerlendirilmelidir.
Children with neurological disorders are highly susceptible to infectious diseases, which can significantly worsen their prognosis. Timely and complete vaccination is the most effective, low-cost intervention to protect these patients and improve their quality of life. Concerns regarding potential adverse events, such as febrile seizures, should not serve as reasons to delay or avoid routine immunization protocols. Unless specific immunosuppressive therapies require adjustment, these patients should adhere to standard vaccination schedules to ensure optimal health protection.
Referanslar
Esposito S, Passera S. Vaccination in patients with disorders of the muscle and neuromuscular junction. Expert Rev Vaccines. 2013;12(11):1341-9.
Kondolot M, Bayram AK, Canpolat M, et al. Vaccination Status of Children with Neurological Disorders and Associated Factors. Turkish Journal of Pediatric Disease. 2017;11:265-70.
T.C Sağlık Bakanlığı. Halk sağlığı Genel Müdürlüğü. Aşı Portalı. (10.07.2021 tarihinde https://asi.saglik.gov.tr/asi-takvimi2 adresinden ulaşılmıştır).
Koç F, Gökçay G. (2020). Çocuklarda Aşı Uygulamaları. Gökçay G, Beyazova U, editörler. İlk Beş Yaşta Çocuk Sağlığı İzlemi. 2. Edition. İstanbul: Nobel. p.471-5.
Li X, Lin Y, Yao G, Wang Y. The Influence of Vaccine on Febrile Seizure. Current Neuropharmacology. 2018;16(1):59-65.
Kawai AT, Martin D, Kulldorf M, et al. Febrile Seizures After 2010-2011 Trivalent Inactivated Influenza Vaccine. Pediatrics. 2015;136(4):848-55.
Sun Y, Christensen J, Hviid A, et al. Risk of Febrile Seizures and Epilepsy After Vaccination with Diphteria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenza Type B. JAMA. 2012;307(8):823-31.
Macartney K, Gidding HF, Trinh L, et al. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. JAMA Pediatr. 2017;171(10):992-8.
Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: Recommendations of The Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports. 2011;60(2):1-64. Erratum in: MMWR Recomm Rep. 2011 Jul 29;60:993. PMID: 21293327
Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and Rates of Adverse Reactions Associated with DTP and DT Immunizations in Infants and Children. Pediatrics. 1981;68(5):650-60.
Vestergaard M, Hviid A, Madsen KM. MMR Vaccination and Febrile Seizures: Evaluation of Susceptible Subgroups and Long-Term Prognosis. JAMA. 2004;292(3):351-357.
Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of Convulsion and Aseptic Meningitis Following Measles, Mumps, Rubella Vaccination in The United Kingdom. Am. J. Epidemiol. 2007;165(6):704-9.
Deng L, Wood N, Danchin M. Seizures Following Vaccination in Children: Risks, Outcomes and Management of Subsequent Revaccination. Aust J Gen Pract. 2020;49(10):644-9.
Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Updated May 4, 2021. (21/07/2021 tarihinde https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf adresinden ulaşılmıştır).
Tartof SY, Tseng HF, Liu IL, et al. Inpatient Admission for Febrile Seizure and Subsequent Outcomes Do Not Differ in Children With Vaccine-Associated Versus Non-Vaccine Associated Febrile Seizures. Vaccine. 2014;32(48):6408–14.
Deng L, Wood N, Macartney K, et al. Developmental Outcomes Following Vaccine–Proximate Febrile Seizures in Children. Neurology.2020;95(3):e226-38.
Jackson LA, Carste BA, Malais D, Froeschle J. Retrospective Population-Based Assessment of Medically Attended Injection Site Reactions, Seizures, Allergic Responses and Febrile Episodes After Acellular Pertussis Vaccine Combined With Diphtheria and Tetanus Toxoids. Pediatr Inf Dis J.2002;21(8):781–6.
Alderslade R, Bellman MH, Rawson NSB, Ross EM, Miller DL. (1981) The National Childhood Encephalopathy Study: A Report on 1000 Cases of Serious Neurological Disorders in Infants and Young Children From the NCES Research Team. Department of Health and Social Security. Whooping Cough: Reports from the Committee on the Safety of Medicines and the Joint Committee on Vaccination and Immunization. London: Her Majesty’s Stationery Office 79–169.
World Health Organization. Vaccine Safety and False Contrindications to Vaccination- Training Manual. World Health Organization (2017). (17/08/2021 tarihinde https:// www.euro.who.int/__data/assets/pdf_file/0009/351927/WHO-Vaccine-Manual.pdf adresinden ulaşılmıştır).
Velipaşaoğlu S. (2020). Özel Durumlarda Bağışıklama. Gökçay G, Beyazova U, editörler. İlk Beş Yaşta Çocuk Sağlığı İzlemi. 2. Baskı. İstanbul: Nobel Tıp Kitabevleri. p.595-610.
Berkovic SF, Harkin L, McMahon JM, et alDe Novo Mutations of The Sodium Channel Gene SCN1A in Alleged Vaccine Encephalopathy: A Retrospective Study. Lancet Neurol. 2006;5(6):488–92.
Pruna D, Balestri P, Zamponi N, et al. Epilepsy and Vaccinations: Italian Guidelines. Epilepsia. 2013;54(7):13-22.
Tro-Bauman B, von Spiczak S, Lotte J, et al. A Retrospective Study of the Relation Between Vaccination and Occurrence of Seizures in Dravet Syndrome. Epilepsia. 2011;52(1):175–8.
Tanabe T, Awaya Y, Matsuishi T, et al. Management of and Prophylaxis Against Status Epilepticus in Children with Severe Myoclonic Epilepsy in Infancy (SMEI; Dravet syndrome)–A Nationwide Questionnaire Survey in Japan. Brain Dev. 2008;30(10):629-35.
American Academy of Pediatrics. Influenza. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Disease. 32 st ed. Itasca, IL: American Academy of Pediatrics; 2021. p.447-56.
Ohya T, Nagai T, Araki Y, et al. A Pilot Study on The Changes in Immunity After ACTH Therapy in Patients With West Syndrome. Brain & Development. 2009;31(10):739-43.
Esposito S, Cecinati V, Brescia L, et al. Vaccinations in Children With Cancer.Vaccine.2010;28(19):3278-84.
Esposito S, Bruno C, Berardinelli A. Vaccination Recommendations for Patients With Neuromuscular Disease. Vaccine. 2014;32(45):5893-5900.
Keren R, Zaoutis TE, Bridges CB, et al. Neurological and Neuromuscular Disease as a Risk Factor for Respiratory Failure in Children Hospitalized With Influenza Infection. JAMA. 2005;294(17):2188-94.
Coffin SE, Zaoutis TE, Rosenquist AB, et al. Incidence, Complications, and Risk Factors For Prolonged Stay in Children Hospitalized With Community-Acquired Influenza. Pediatrics. 2007;119(4):740-8.
Arnold SR, Wang EE, Law BJ, et al. Variable Morbidity of Respiratory Syncytial Virus Infection in Patients With Underlying Lung Disease: A Review of The PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J. 1999;18(10):866-9.
Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 2012;14:275–85.
Principi N, Esposito S. Adolescents and Vaccines in the Western World. Vaccine. 2013;31(46):5366-74.
de Martino M, Chiappini E, Galli L. Vaccines and Autoimmunity. Int J Immunopathol Pharmacol. 2013;26(2):283-90.
American Academy of Pediatrics. (Immunization In Special Circumstances) In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases.32 st ed. Itasca, IL:American Academy of Pediatrics: 2021.p.72-88.
Buch MH, Smolen JS, Betteridge N, et al. Updated Consensus Statement on The Use of Rituximab in Patients With Rheumatoid Arthritis. Ann Rheum Dis. 2011;70(6):909-920.
Furer V, Rondaan C, Heijstek MW, et al. 2019 Update Of EULAR Recommendations For Vaccination in Adult Patients With Autoimmune Inflammatory Rheumatic Diseases. Ann Rheum Dis. 2020;79(1):39-52.
US Centers for Disease Control and Prevention. Immunization and Immunocompetence. (06/01/2021 tarihinde https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence. html adresinden ulaşılmıştır).
Crew PE, McNamara L, Waldron PE, et al. Antibiotic Prophylaxis in Vaccinated Eculizumab Recipients Who Developed Meningococcal Disease. J Infect. 2020;80(3):350-371.
Mbaeyi Sarah A., Bozio Catherine H., Duffy Jonathan, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR. Recommendations and Reports. 2020;69(9):1–41.
US Centers for Disease Control and Prevention. Pneumococcal Vaccination: Summary of Who and When to Vaccinate. (30/12/2020 tarihinde https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html adresinden ulaşılmıştır).
Advisory Committee on Immunization Practices. Altered Immunocompetence. General Best Practice Guidelines for Immunization: Best Practices Guidance of The Advisory Committee on Immunization Practices(ACIP). (30/12/2020 tarihinde https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html adresinden ulaşılmıştır).
Ljugman P. (2013). Vaccination of Immunocompromised Hosts. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA, (eds). 6th edition. Elsevier Inc: Saunders, 1243-56.
Murthy BP, MStat EZ, Saelee R, et al. COVID-19 Vaccination Coverage Among Adolescents Aged 12–17 Years -United States, December 14, 2020–July 31, 2021. Morbidity and Mortality Weekly Report. US Department of Health and Human Services/Centers for Disease Control and Prevention.2021;70(35):1206-13.
Gilroy J. (2000). Basic Neurology (3rd ed). Mc Graw Hill, New York, St. Louis, San Francisco, p 199-223.
Sadiq SA, Miller JR. (1995). Demyelinating Diseases. In: Rowland LP (edt), Merritt’s Texbook of Neurology. Williams & Wilkins. Baltimore, Philadelphia, Hong Kong, p. 805-9.
Solmaz I, Anlar B. Immunızatıon In Multıple Sclerosıs And Other Childhood Immune Mediated Disorders of The Central Nervous System: A Review of the Literature. European Journal of Paediatric Neurology. 2021; doi: https://doi.org/10.1016/j.ejpn.2021.06.002.
Langer-Gould A, Qian L, Tartof SY, et al. Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases. JAMA Neurol. 2014;71(12):1506-13.
Mouchet J, Salvo F, Raschi E, et al. Hepatitis B Vaccination And The Putative Risk Of Central Demyelinating Diseases - A Systematic Review And Meta-Analysis. Vaccine. 2018;36(12):1548-55.
Meggiolaro A, Migliara G, La Torre G. Association Between Human Papilloma Virus (HPV) Vaccination And Risk Of Multiple Sclerosis: A Systematic Review. Hum Vaccin Immunother. 2018;14(5):1266-74.
Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, et al. Risk Of Autoimmune Diseases And Human Papilloma Virus (HPV) Vaccines: Six Years of Case-Referent Surveillance. J Autoimmun. 2017;79:84-90.
Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis. 2018;5(8):ofy174.
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of The Immunocompromised Host. Clin Infect Dis. 2014;58(3):e44-100.
von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, et al. Immune Response To Vaccines is Maintained in Patients Treated with Dimethyl Fumarate. Neurol Neuroimmunol Neuroinflamm. 2018;5(1):e409.
Kaufman M, Pardo G, Rossman H, et al. Natalizumab Treatment Shows No Clinically Meaningful Effects on Immunization Responses in Patients with Relapsing-Remitting Multiple Sclerosis. J Neurol Sci. 2014;341(1-2):22-7.
Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide Effect on Immune Response to Influenza Vaccine in Patients with Multiple Sclerosis. Neurology. 2013;81(6):552-8.
Reyes S, Ramsay M, Ladhani S, et al. Protecting People with Multiple Sclerosis Through Vaccination. Pract Neurol. 2020;20(6):435-45.
U.S. Food and Drug Administration. Aubagio (teriflunamide). Revised June 2016 (26.07.2021 tarihinde https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202992s003lbl.pdf adresinden ulaşılmıştır).
Riva A, Barcella V, Benatti SV, et al. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. Mult Scler. 2021;27(3):347-59.
Giovannoni G, Hawkes C H., Lechner-Scott J, et al. COVID-19 Vaccines And Multiple Sclerosis Disease-Modifying Therapies. Multiple Sclerosis and Related Disorders. 2021;53,103155.
Metze C, Winkelmann A, Loebermann M, et al. Immunogenicity and Predictors of Response to a Single Dose Trivalent Seasonal Influenza Vaccine in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies. CNS Neurosci Ther. 2019;25(2):245-54.
Olberg HK, Eide GE, Cox RJ, et al. Antibody Response to Seasonal Influenza Vaccination in Patients with Multiple Sclerosis Receiving Immunomodulatory Therapy. Eur J Neurol. 2018;25(3):527-34.
European Medicine Agency. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU. (06/09/2021 tarihinde https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu adresinden ulaşılmıştır).
U.S. Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine. Revised August 2021 (06/09/2021 tarihinde https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine adresinden ulaşılmıştır).
Centers For Disease Control and Prevention. COVID-19 Vaccines for Children and Teens. Updated August 2021. (06/09/2021 tarihinde https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/adolescents.html ulaşılmıştır).
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immuncompromised Host. Clin Infect Dis. 2014;59(1):44-100.
